Despite rapid scientific advances and growing interest in alternatives to traditional antibiotics, phage therapy —a method of treating bacterial infections using bacteriophages —still remains on the fringes of global medical practice. This method has the potential to become a key solution in the fight against antibiotic resistance. However, a number of serious challenges stand in the way of its acceptance as a standard of care.

The lack of regulation is the main obstacle to recognition

One of the main reasons why phage therapy has not yet become widespread globally is the lack of consistent regulatory framework . In most countries, bacteriophages are still not clearly classified—are they biologics, drugs, or experimental therapies? The answers vary. For example, in the US and most EU countries, bacteriophages do not have an approved status, which hinders their clinical use.

As a result, phage therapeutic approaches are often limited to individual programs or clinical trials. The lack of global regulatory standards hinders investment, protocol development, and mass adoption.

The problem of patenting and commercial attractiveness

Phages are naturally occurring viruses , meaning they are difficult to patent in their natural form. This makes them less attractive to commercially driven pharmaceutical giants. Companies are reluctant to invest in technologies that cannot be protected from being copied by competitors.

The only solution is to develop genetically modified or synthetic bacteriophages, or patent delivery and purification methods. But this requires a completely different level of funding, which is often in short supply. Thus, the phage therapy market remains almost exclusively a field for scientists, enthusiasts, and small laboratories.

Lack of large-scale clinical trials

Another important reason why phage therapy hasn't become medically mainstream is the lack of large-scale randomized clinical trials. In medicine, these studies are considered the "gold standard" for demonstrating efficacy.

The problem is that phages are highly specific by nature. A single bacteriophage can effectively target only a specific bacterial strain. This makes conducting large-scale studies difficult: therapy must be tailored to each patient, making the development of a single, universal phage therapy impossible.

Nevertheless, modern research in personalized medicine offers hope for a change. Combining phage therapy with DNA sequencing technologies, bioinformatics, and automated platforms will open up new opportunities for standardizing and scaling research.

Complexity of production and storage

Unlike antibiotics, which can be mass-produced and stored for years, bacteriophages require special conditions. They must be purified from toxins and endotoxins, stored at the appropriate temperature, and undergo strict quality control.

This complicates logistics and mass production. Furthermore, new bacterial strains require constant updating of phage banks. Although some companies are already working on creating phage libraries, this requires regular updates and significant resources.

Mistrust from the medical community

Despite decades of experience using bacteriophages in Georgia, Poland, and other Eastern European countries, many doctors worldwide remain cautious about them. This is partly due to a lack of high-quality clinical data, partly due to inertia in thinking and a distrust of "alternative medicine."

Medical education still pays extremely little attention to phage therapy. The curricula of leading universities around the world barely mention the topic or don't mention it at all. This creates a vicious cycle: doctors don't know about phages, so they don't recommend them, which means demand and research remain limited.

Legal barriers and fear of the unknown

Another challenge is the legal liability of doctors. In the event of an adverse reaction or ineffectiveness of phage therapy, a physician may face accusations of using an unproven method. This deters even those specialists who would be willing to prescribe bacterial viruses as a therapeutic tool.

There's also public wariness. Patients are often frightened by the words "virus" or "bacteriophage." Although these aren't pathogens for humans, but rather are friendly to our bodies, this image requires communication support. Phage therapy needs to be promoted as an innovative yet safe medical approach.

Overcoming Barriers: Strategic Steps Forward

The solution to regulatory uncertainty lies in international cooperation. Harmonized approaches to the classification, licensing, and quality control of bacteriophages are needed. The WHO, EMA, and FDA should initiate the creation of separate framework documents defining the requirements for phage preparations.

At the same time, governments can stimulate research in phage therapy by introducing grants, tax incentives, and support for innovative biotech startups. Successful examples of countries that have created national phage therapy programs could form the basis for a global movement.

Education and Trust: The Foundation for Lasting Change

To change the attitudes of medical professionals, phage therapy must be integrated into medical school curricula. Practical courses and case studies from clinics where effective viruses are already saving patients will help dispel stereotypes.

It's also important to educate patients, explaining that phages aren't pathogens, but rather our microscopic allies. Communication campaigns using modern platforms, videos, and infographics will help change perceptions.

Personalized Phage Therapy: The Future That's Already Begun

Thanks to advances in sequencing technologies, big data, and artificial intelligence, phage therapy is becoming personalized. Instead of universal antibiotics that kill everything, we can offer viruses and bacteria that precisely destroy pathogens without harming beneficial microflora.

This approach is not only more effective but also reduces the risk of side effects. In the long term, this could lead to a transformation of the healthcare system—from a one-size-fits-all approach to truly individualized treatment.

Conclusion: not an alternative, but a supplement

Phage therapy should not be seen as a replacement for antibiotics, but as a powerful complement. In a world where microbial resistance is growing, we need every tool available. Bacteria hunters, these natural biological agents, have the potential to save thousands of lives if we overcome administrative, scientific, and psychological barriers.

Whether bacteriophages will become an integral part of the medicine of the future depends on the synergy between science, the medical community, governments, and society. And while the path is challenging, it is worth the effort.